In addition, every biomarker was clustered into different subgroups on the column side according to their color patterns in the center grids of heatmap
Phase 2a clinical testing of a first-in-class small-molecule compound that targets a p75 neurotrophin receptor, for example, demonstrated potential efficacy in slowing AD pathology in participants with mild to moderate AD, as measured by CSF biomarkers amyloid beta40 and amyloid beta42
And that last line is how they seek to validate the rest of this commercial
on key thoughts nejm.org/doi/full/10.10 Excellent trial conduct Vital status known in 98.6% High rates of treatment adherence (89% throughout trial) Study treatment discontinuation modest (26%) but reasonable given #FLOW conducted "intra-pandemic" (recruitment June '19 to May '21) & long follow-up (3.4 years)Large, clinically meaningful, & compelling effects on all key endpoints: Kidney disease progression CV outcomes Mortality Sema mortality by 20% (driven by CV death!) w an NNT of just 39 to prevent a death over 3y Curves visually appear to separate after 12mo.No unexpected safety signals Safety profile largely consistent with trials of prior #GLP1RA and incretin-based therapies SAEs with semaglutide driven by lower infections & CV events AEs leading to drug discontinuation, expectedly related to GI side effects#FLOW also affirms #CKD as a modifiable pathway to CV risk Cardiologists must be key partners in implementation of kidney #GDMT in high-risk patients Especially as "pillars" for #CKM largely overlapping in 2024
Please see attached hydrostatic bodyfat test results showing this: What you see: Before hCG: 59 lbs fat After hCG: 21 lbs fat Results: 38 lbs of bodyfat, left my body, through my liver
